Therapy Areas: Oncology
AstraZeneca reports survival gains in Phase III bladder cancer trial
14 May 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) reported on Thursday that interim Phase III VOLGA trial results showed that perioperative Imfinzi combined with n...
Creatv Bio opens CLIA-certified laboratory in Monmouth Junction, NJ
14 May 2026 - Creatv Bio, a division of Creatv MicroTech Inc, a liquid biopsy-based cancer diagnostic testing company, announced on Wednesday that it has opened its full service CLIA-certified laborat...
SOPHiA GENETICS and Synnovis partner to expand NHS liquid biopsy testing
...
AngioDynamics reports 24-month PRESERVE data showing durable NanoKnife outcomes in prostate cancer
13 May 2026 - Medical technology company AngioDynamics Inc (NASDAQ: ANGO) reported on Wednesday that the two-year results from the PRESERVE pivotal trial of its NanoKnife System demonstrated sustained...
Kelun-Biotech's SKB118 PD-1 x VEGF bispecific antibody receives Chinese regulatory Investigational New Drug approval
13 May 2026 - Sichuan Kelun-Biotech Biopharmaceutical Co, Ltd (6990.HK) a China-based biopharmaceutical company, announced on Tuesday that it has received a clinical trial notice from China s Center f...
Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma
13 May 2026 - Servier, a France-based pharmaceutical company, announced on Tuesday that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Emi-Le, an investiga...